Apellis Pharmaceuticals Inc’s recent filing unveils that its Former Officer Townsend Adam J. acquired Company’s shares for reported $3.92 million on May 12 ’25. In the deal valued at $17.76 per share,220,961 shares were bought.
Then, Chopas James George sold 183 shares, generating $4,543 in total proceeds. Upon selling the shares at $24.82, the VP/Chief Accounting Officer now owns 47,955 shares.
Before that, Chopas James George bought 183 shares. Apellis Pharmaceuticals Inc shares valued at $4,543 were divested by the Officer at a price of $24.82 per share.
Raymond James downgraded its Apellis Pharmaceuticals Inc [APLS] rating to an Outperform from a a Strong buy in a research note published recently. A number of analysts have revised their coverage, including BofA Securities’s analysts, who decreased its forecast for the stock in early May from “a Buy” to “a Neutral”. Cantor Fitzgerald began covering APLS with “an Overweight” recommendation on April 29, 2025. Goldman revised its rating on December 17, 2024. It rated APLS as “a Neutral” which previously was an “a Buy”.
Price Performance Review of APLS
On Tuesday, Apellis Pharmaceuticals Inc [NASDAQ:APLS] saw its stock jump 0.98% to $19.58. Over the last five days, the stock has gained 4.04%. Apellis Pharmaceuticals Inc shares have fallen nearly -38.64% since the year began. Nevertheless, the stocks have fallen -52.30% over the past one year.
How much short interest is there in Apellis Pharmaceuticals Inc?
A steep rise in short interest was recorded in Apellis Pharmaceuticals Inc stocks on 2025-05-15, growing by 0.41 million shares to a total of 27.25 million shares. Yahoo Finance data shows the prior-month short interest on 2025-04-15 was 26.83 million shares. There was a rise of 1.51%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on November 21, 2024 when Morgan Stanley began covering the stock and recommended ‘”an Equal-weight”‘ rating along with a $31 price target.
